We are live on
!
Find out more
SCM
Sarissa Capital Management Portfolio holdings
AUM
$158M
1-Year Est. Return
103.7%
This Fund
S&P 500
This Quarter
Est. Return
-20.72%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$451M
AUM Growth
-$2.06M
(-0.45%)
Cap. Flow
+$117M
Cap. Flow
% of AUM
26%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
11
New
2
Increased
4
Reduced
1
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Puma Biotechnology
PBYI
|
+$40.3M |
| 2 |
Ironwood Pharmaceuticals
IRWD
|
+$39.5M |
| 3 |
AGN
Allergan plc
AGN
|
+$33.2M |
| 4 |
MDCO
Medicines Co
MDCO
|
+$20M |
| 5 |
Innoviva
INVA
|
+$8.38M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$21.1M |
| 2 |
NVLN
Novelion Therapeutics Inc. Common Shares
NVLN
|
+$3.03M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Biogen
BIIB
$30B
| $139M | 30.8% |
461,858
| – | – |
|
|
2
Innoviva
INVA
$1.55B
| $88.1M | 19.53% |
5,051,100
+516,100
| +11% | +$8.38M |
|
|
AGN
3
DELISTED
Allergan plc
AGN
| $73M | 16.19% |
546,500
+202,500
| +59% | +$33.2M |
|
|
4
Ironwood Pharmaceuticals
IRWD
$696M
| $64.8M | 14.35% |
7,465,246
+3,444,929
| +86% | +$39.5M |
|
|
MDCO
5
DELISTED
Medicines Co
MDCO
| $53.2M | 11.8% |
2,781,000
+859,000
| +45% | +$20M |
|
|
6
Puma Biotechnology
PBYI
$404M
| $27.3M | 6.06% |
+1,343,000
| New | +$40.3M |
|
|
ICPT
7
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $5.44M | 1.21% |
54,000
-203,500
| -79% | -$21.1M |
|
|
SHPG
8
DELISTED
Shire pic
SHPG
| $174K | 0.04% |
1,000
| – | – |
|
9
AbbVie
ABBV
$443B
| $92K | 0.02% |
1,000
| – | – |
|
|
MRTX
10
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $42K | 0.01% |
+1,000
| New | +$39.9K |
|
|
NVLN
11
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
| – | – |
-1,025,000
| Closed | -$3.03M |
|
Similar funds
4A
DAM
PCP
CF
HEM
SF
AC
EP
Sarissa Capital Management's Q4 2018 Portfolio in Review
As of Q4 2018, Sarissa Capital Management held 11 positions worth $451M, down 0.45% from $453M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Sarissa Capital Management deployed $117M of net new capital in Q4 2018, opening 2 new positions and adding to 4 existing holdings. Its largest new stake was Puma Biotechnology: 1,343,000 shares worth $27.3M.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 87% a quarter earlier.
On the sell side, the largest reduction was Intercept Pharmaceuticals, Inc., an estimated $21.1M trimmed.
- Sarissa Capital Management's largest Q4 2018 buy was Puma Biotechnology: 1,343,000 shares worth $27.3M.
- Sarissa Capital Management added most to Ironwood Pharmaceuticals in Q4 2018, an estimated $39.5M increase.
- Sarissa Capital Management's biggest Q4 2018 reduction was Intercept Pharmaceuticals, Inc., cutting an estimated $21.1M.
- Sarissa Capital Management fully exited Novelion Therapeutics Inc. Common Shares in Q4 2018, selling an estimated $3.03M.
- Sarissa Capital Management's ten largest holdings make up 100% of its $451M portfolio in Q4 2018.
- Sarissa Capital Management opened 2 new positions and closed 1 in Q4 2018.
- Sarissa Capital Management's portfolio value fell 0.45% quarter-over-quarter to $451M.
Based on Sarissa Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.